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Survival in children with relapsed/refractory acute myeloidleukemia is unsatisfactory. Treatment consists of one course of flu-darabine, cytarabine and liposomal daunorubicin, followed by flu-
darabine and cytarabine and stem-cell transplantation. Study ITCC
020/I-BFM 2009-02 aimed to identify the recommended phase II dose
of clofarabine replacing fludarabine in the abovementioned combina-
tion regimen (3+3 design). Escalating dose levels of clofarabine (20-40
mg/m2/day x 5 days) and liposomal daunorubicin (40-80 mg/m2/day)
were administered with cytarabine (2 g/m2/day x 5 days). Liposomal
DNR was given on day 1, 3 and 5 only. The cohort at the recommend-
ed phase II dose was expanded to make a preliminary assessment of
anti-leukemic activity. Thirty-four children were enrolled: refractory 1st
(n=11), early 1st (n=15), ≥2nd relapse (n=8). Dose level 3 (30 mg/m2 clo-
farabine; 60 mg/m2 liposomal daunorubicin) appeared to be safe only in
patients without subclinical fungal infections. Infectious complications
were dose-limiting. The recommended phase II dose was 40 mg/m2
clofarabine with 60 mg/m2 liposomal daunorubicin. Side-effects mainly
consisted of infections. The overall response rate was 68% in 31
response evaluable patients, and 80% at the recommended phase II
dose (n=10); 22 patients proceeded to  stem cell transplantation. The 2-
year probability of event-free survival (pEFS) was 26.5±7.6 and proba-
bility of survival (pOS)  32.4±8.0%. In the 21 responding patients, the
2-year pEFS was 42.9±10.8 and pOS 47.6±10.9%. Clofarabine expo-
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ABSTRACT
Introduction 
Despite enhanced cure rates for pediatric acute myeloid
leukemia (AML), relapsed patients still suffer from poor
clinical outcome,1 especially those who relapse within one
year of diagnosis.2 Recently, a randomized phase III study
in relapsed/refractory AML revealed an improved early
treatment response when liposomal daunorubicin (DNX)
was added to the FLAG (fludarabine, cytarabine and gran-
ulocyte-colony stimulating factor (G-CSF)) regimen.2
Although this did not translate into a survival benefit [4-
year probability of survival (pOS) of 38±3%], in Europe,
the combination of FLAG and DNX (FLAG-DNX) fol-
lowed by stem cell transplantation (SCT) was considered
the standard treatment for children with AML in first
relapse.2,3 For several reasons, including data obtained in
adults, subsequently G-CSF priming was deleted from the
FLAG regimen4,5 and the current standard is FLA-DNX.
Intensified relapse therapy increased survival over time,6
but insufficient cure rates in the 70% range (pOS),3 and
potential long-term toxicities such as anthracycline car-
diomyopathy when cumulative dosages exceed 300-400
mg/m2,7,8 mean that  novel chemotherapy combinations
must be developed. 
Clofarabine, a structural hybrid of fludarabine and
cladribine, was developed to enhance efficacy and stabili-
ty of the drug, while reducing the formation of toxic com-
pounds like 2-F adenine compared to previous nucleoside
analogs.9,10 Inhibition of DNA polymerase and ribonu-
cleotide reductase as well as induction of apoptosis,10 and
enhanced accumulation of cytarabine may contribute to
the drug's high antitumor activity.11
The first pediatric phase I study of clofarabine identified
a maximum tolerated dose (MTD) of 52 mg/m2/day, with
reversible hepatotoxicity and skin rash as dose-limiting
toxicities.12 Based on a phase II study, clofarabine was
approved in 2004 for relapsed pediatric ALL.13 However, in
relapsed pediatric AML, activity of clofarabine was not
confirmed, with a response rate of only 26%, mainly con-
sisting of partial responses, probably due to the inclusion
of heavily pre-treated patients.13 In contrast, in adult AML,
clofarabine showed antileukemic activity in several early
phase studies.14-16 Randomized data showed that, even
though remission rates were improved in untreated older
patients with AML and high-risk myelodysplastic syn-
drome (MDS), no survival benefit  of clofarabine (20
mg/m2/d for 5 days) over low-dose cytarabine was
shown.17 Moreover, another randomized study comparing
cytarabine with clofarabine (20 mg/m2/d for 5 days) in
induction courses I and II in elderly AML also failed to
show a survival benefit.18 However, a recent study by the
HOVON-group did show a survival advantage for patients
randomized to clofarabine in intermediate-risk AML sub-
sets, albeit at a very low dose of 10 mg/m2/d for five days
added to induction courses I and II.19
In pediatric ALL, clofarabine combination therapy was
developed to overcome resistance, e.g. combinations
with cyclophosphamide, or etoposide and cyclophos-
phamide, or topotecan, vinorelbine and thiopeta.20-23 In
children with relapsed/refractory AML, clofarabine (52
mg/m2/d for 5 days) with cytarabine (1 g/m2/d for 5 days)
resulted in a 3-year pOS of 46%±27% in responders.24 In
the CLOUD study, 9 children with relapsed/refractory
AML were treated with clofarabine (30 mg/m2/d for 5
days) and liposomal daunorubicin (60 mg/m2, days 1, 3
and 5); 33% obtained complete remission (CR) and were
subsequently transplanted.25
In this study, we aimed to combine clofarabine with
high-dose cytarabine and liposomal daunorubicin as in the
FLA-DNX regimen, replacing fludarabine with clofarabine
assuming that this may have greater anti-leukemic poten-
tial when tolerable. The treatment schedule was based on
an adapted ‘Faderl regimen’ developed in adult AML.26,27
Methods
Study ITCC-020 (EUDRA-CT 2009-009457-13; Dutch Trial
Registry number 1880) was an investigator-initiated open-label
phase IB dose-escalation study sponsored by Erasmus MC,
Rotterdam, the Netherlands. Patients were enrolled in 15 centers
in 5 countries within the Innovative Therapies for Children with
Cancer (ITCC) consortium. 
Study design
The primary objective was to establish the MTD and recom-
mended phase II dose (RP2D) of clofarabine in combination with
cytarabine and DNX in relapsed/refractory pediatric AML. Dose-
limiting toxicities were evaluated in the first course only.
Secondary objectives included tabulation of additional safety and
tolerability data across both treatment courses, preliminary esti-
mation of response, event-free survival (EFS), and overall survival
(OS), and the pharmacokinetics (PK) of clofarabine in this combi-
nation [serum and cerebrospinal fluid (CSF)]. A classical 3+3
design was used with dose escalation to MTD, after which the
cohort was expanded (n=10) at the RP2D. Separate expansion
cohorts were planned for dose level (DL) 1-4 and for DL5 (in early
1 first relapse only), respectively, when considered safe.
Patient eligibility
Pediatric patients below 19 years of age with early 1st relapse
(within 12 months from initial diagnosis), refractory 1st relapse (≥
20% blasts in the bone marrow after the first course of standard
re-induction therapy), or those with at least a second relapsed
AML were eligible. Only patients with early 1st relapse without
prior SCT were eligible for DL5. Inclusion and exclusion criteria
are described in Online Supplementary Methods S1, and included
recovery from prior organ toxicity. An amendment in November
2011 excluded patients with evidence for subclinical fungal infec-
tions using high-resolution computed tomography (CT) scan of
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sure in plasma was not significantly different from that in single-agent studies. In conclusion, clofara-
bine was well tolerated and showed high response rates in relapsed/refractory pediatric acute myeloid
leukemia. Patients with (sub)clinical fungal infections should be treated with caution. Clofarabine has
been taken forward in the Berlin-Frankfurt-Münster study for newly diagnosed acute myeloid
leukemia. The Study ITCC-020 was registered as EUDRA-CT 2009-009457-13; Dutch Trial Registry
number 1880. 
the thorax, and elevated serum levels of galactomannan. 
All patients/parents had to provide written informed consent
according to local law and regulations, after the institutional
review boards of the participating institutes approved the study.
The study was conducted in accordance with good clinical prac-
tice guidelines and the Declaration of Helsinki.
Treatment
Clofarabine and DNX dosages were escalated from 20-40
mg/m2/day at days 1-5, and 40-80 mg/m2/day at days 1, 3 and 5,
respectively, whereas the dose of cytarabine was fixed at 2 g/m2/d
for days 1-5 (Table 1, detailed information in Online Supplementary
Methods S2). DL5 (DNX 80 mg/m2/day at days 1, 3 and 5) was con-
sidered as a separate cohort with restricted inclusion criteria. This
cohort was added as up-front pediatric AML protocols use DNX
at this dose level rather than 60 mg/m2/d28 (Figure 1).
Safety and efficacy evaluations 
Adverse events (AEs) were graded according to the Common
Terminology Criteria for Adverse Events v.3.0. Dose Limiting
Toxicities (DLT) were defined as grade 3 or 4 non-hematologic
AEs and hematologic AEs lasting longer than 42 days, limited to
the first course, and at least possibly drug-related, with some
exceptions (definitions and efficacy evaluation in Online
Supplementary Methods S3 and Table S1).
Statistical analysis
Dosing and efficacy were analyzed using descriptive statistics.
Survival estimates were computed by Kaplan-Meier. The database
lock for this analysis was set at 11th February 2018. All analyses
were performed with Stata v.13.1.
Further information concerning pharmacokinetics and statistical
analysis is available in Online Supplementary Methods S4, Methods
S5 and Table S2.
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Table 1. Dose levels of clofarabine, liposomal daunorubicin and cytarabine.
Age ≥ 1 year Clofarabine DNX Ara-C
(Age < 1 year)
Dose level -1 15 mg/m2/d x 5 d 40 mg/m2/day 1-3-5 2 gr/m2/d x 5 d
(0.5 mg/kg/d x5 d) (1.3 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 1 (starting dose) 20 mg/m2/d x 5 d 40 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
(0.7 mg/kg/d x 5 d) (1.3 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 2 30 mg/m2/d x 5 d 40 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
(1.0 mg/kg/d x 5 d) (1.3 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 3A 30 mg/m2/d x 5 d 60 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
(1.0 mg/kg/d x 5 d) (2.0 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 3B* 30 mg/m2/d x 5 d 60 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
(1.0 mg/kg/d x 5 d) (2.0 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 4 40 mg/m2/day x 5 d 60 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
(1.3 mg/kg/day x 5 d) (2.0 mg/kg/d 1-3-5) (70 mg/kg/d x 5 d)
Dose level 5** 40 mg/m2/day x 5 d 80 mg/m2/d 1-3-5 2 gr/m2/d x 5 d
Ara-C: cytarabine; DNX:liposomal daunorubicin. *Dose level 3B: cohort 3 was repeated after an amendment implementing screening for subclinical fungal infections. **Dose
level 5: this cohort was open for patients with early 1st relapse of acute myeloid leukemia without prior stem cell transplantation only.  Dosages in brackets are for children below
1 year of age or below 10 kg body weight.
Figure 1. Treatment schedule. Clofarabine
was administered intravenously (IV) in 2
hours (h) (days 1-5); liposomal daunoru-
bicin (DNX) in 1 h (days 1, 3, 5); DNX in 1 h
(days 1, 3, 5), starting 30 minutes after the
end of clofarabine; cytarabine was adminis-
tered (IV) in 3 h (days 1-5), starting 3 h after
the end of clofarabine. Intrathecal therapy
was administered at day 6 with cytarabine
for prophylaxis, or triple therapy (cytarabine
and methotrexate and prednisolone) with
age-adjusted dosages in case of central




Between 10th May  2010 and 28th May 2014, 34 AML
patients (early first relapse, n=15; refractory first relapse,
n=11; ≥2nd relapse, n=8) were recruited. The median age
was 8.3 years (range 1.0-19.6 years); the median WBC
4.6x109/L (range 0.3-326x109/L), and 41% of patients were
female. We had conclusive cyto(genetic) data from initial
diagnosis in 30 of 34 patients, and from time point of inclu-
sion in this study in 23 patients. None of these karyotypes
included good risk characteristics such as t(8;21)(q22;q22) or
inv(16)(p13q22)/t(16;16)(p13;q22). Eighteen patients had
been pre-treated with FLAG-DNX reinduction according to
protocol AML-BFM 2001/01.2 Twelve patients had
received a prior SCT (4 in CR1; 7 in CR2; and 1 unknown),
including one patient with 2 prior SCTs. For 32 of 34
patients, prior cumulative dose of anthracycline was calcu-
lated using the equivalent formula, as previously
described.29 With respect to the missing equivalent doses,
prior amsacrine and prior liposomal daunorubicin were not
included in the calculation. Prior anthracycline dosages are
heterogenous in this cohort (range 80-686 mg/m2). Detailed
patients' characteristics are provided in Table 2. 
A total of 46 CLARA-DNX cycles were administered: 12
patients received two cycles (1 in DL3A; 2 in DL3B; 6 in
DL4; 3 in DL5). In 31 patients, cycle 1 was given according
to the schedule provided in the protocol. Deviations con-
cerned intrathecal treatment (delayed or deleted in one
patient each), and in one patient cytarabine was halted at
day 3 due to an allergic reaction. The median absolute dose
of clofarabine in cycle one was 160 mg (range 38-380 mg):
165 mg (range 38-456) for DNX, and 9.37 g (range 1.26-19
g) for cytarabine. 
Clofarabine in pediatric AML
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Table 2. Patients’ baseline characteristics. 
Characteristic ALL patients DL1 DL2 DL3A DL3B DL4 DL5
(N=34) (N=4) (N=3) (N=6) (N=6) (N=10) (N=5)
N.    (%) N. N. N. N. N. N.
Age, years
Median 8.3 7.1 14.2 12.9 4.6 10.2 2.4
Range 1.0-19.6 2.8-8.8 1.3-15.6 1.0-17.6 2.5-19.6 1.4-18.8 1.3-16.0
Sex
Male 20 (58.8) 3 3 2 4 6 2
Female 14 (41.2) 1 - 4 2 4 3
FAB at initial diagnosis
M0 4 1 1 - - 2 -
M1 3 - - 1 - - 2
M2 6 - 1 - 2 2 1
M4 4 1 - 2 - 1 -
M5 14 1 - 3 3 5 2
M6 1 - 1 - - - -
Non-classified 2 1 - - 1 - -
Disease status
Early 1st rel 15 - 1 - 3 6 5
Refractory 1st rel 11 2 1 4 2 2 -
≥ 2nd rel 8 2 1 2 1 2 -
WBC at inclusion (x109/L) 
Median 4.6 3 6 3 4 3 4
Range 0.3-326 1-5 1-127 1-326 0-34 0-30 1-6
<10 27 4 2 4 4 6 5
≥10 6 - 1 2 2 2 -
Prior SCT
NO SCT 22 2 1 4 2 8 5
SCT in 1st CR 4 - 1 1 2 - -
SCT in 2nd CR 7 2 1 1 1 2 -
Unknown 1 - - - 1 - -
Pre-treatment with FLA-DNX
Yes 18 4 1 6 3 4 -
No 16 - 2 - 3 6 5
WBC: white blood cells; FAB: French-American-British; SCT: stem cell transplantation; FLA: fludarabine, cytarabine (Ara-C); DNX: liposomal daunorubicin;  CR: complete remis-
sion; DL: dose-level; N: number of patients; rel: relapse.
Safety and tolerability
Initial dose-escalation was halted at DL3 because of
DLTs (3 Grade 3 pulmonary fungal infections (aspergillo-
sis); 1 Grade 3 non-fungal pulmonary infection). An
amendment was issued to repeat cohort 3 after adding
screening for subclinical fungal infections, and only one
DLT in 6 patients was noted (Grade 3 pulmonary candida
infection), hence escalation to DL4 was pursued. In DL4
only one DLT was noted (Grade 4 septicemia). As DL4
was considered safe, this dose-level was expanded to 10
patients. Subsequently, DL5 was opened for patients with
early 1st relapse without prior SCT. At DL5, 2 of 5 patients
experienced DLT (1 Grade 3 pseudomonas aeruginosa celluli-
tis and 1 Grade 3 Gram-negative septicemia), and DL5
was closed therafter (Table 3). Of note, the use of prophy-
lactic antibacterial, antifungals, and antiviral agents was
recommended according to each institution’s guidelines.
Twenty-eight of 34 patients received anti-fungal prophy-
laxis with azoles (either itraconazole, voriconazole or flu-
conazole); 17 of 34 patients were on prophylactic treat-
ment with amphotericin B. Hence 11 of 34 patients
received both azole prophylaxis as well as amphotericin B.
In total, 34 SAEs were reported, mostly consisting of
febrile neutropenia (n=18), documented infections (n=9),
or gastrointestinal SAEs (n=3) (Online Supplementary Table
S3). Non-hematologic AEs related to the first cycle of
study treatment are summarized in Table 3. Overall, the
most common treatment-related AEs were gastrointesti-
nal, pain and infection. These non-hematologic AEs were
mild (Grade 1-2) in most patients. In 2 patients, acute renal
failure was reported, one in combination with a tumor
lysis syndrome. Another patient had a capillary leak syn-
drome with ascites and reduced diuresis. Hematologic
AEs occurred frequently and mostly concerned Grade 3-4
myelosuppression, not resulting in DLTs (data not shown). 
Overall, 21 patients died: 2 as the result of an AE (one
multi-organ failure secondary to febrile neutropenia, 1
hypoxia and respiratory and cardiovascular failure); 15
deaths were due to progressive leukemia following other
treatment attempts in some but not all patients. The
remaining 4 deaths were: SCT procedure related  (n=2),
lung toxicity after allogeneic transplantation with
cytomegalovirus (CMV) reactivation (n=1), and invasive
aspergillosis (n=1).
Efficacy
Of 31 evaluable patients, the ORR was 68% after the 1st
cycle of treatment, including 5 (16%) patients with CR, 15
(48%) patients with CR with incomplete blood count
recovery (CRi), and  1 patient with a partial response (PR)
(3%). Overall response rate (ORR) differed according to
disease phase: 87% in 15 patients with early 1st relapse;
N.K.A. van Eijkelenburg et al.
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Table 3. Non-hematologic adverse events in the first treatment cycle.
AEs
AE term Total Grade 1-2 Grade 3-4
n (%) n (%)
All grades, AEs Patients AEs Patients
n (%)
Gastrointestinal 114 (24) 96(29) 27(79) 18(13) 14(41)
Pain 62(13) 54(17) 16(47) 8(6) 7(21)
Infection 61(13) 9(3) 8(24) 52(36) 27(79)
Metabolic/laboratory 46(10) 37(11) 8(24) 9(6) 5(15)
Skin/dermatological 34(7) 31(9) 24(71) 3(2) 3(9)
Constitutional symptoms 2(5) 22(7) 11(32) 2(1) 2(6)
Pulmonary/upper respiratory 19(4) 13(4) 9(27) 6(4) 3(9)
Cardiac problems including arrhythmia 13(3) 8(2) 7(21) 5(3) 4(12)
Neurology (or ocular/visual) 10(7) 14(3) 11(32) 3(2) 3(9)
Allergy/immunology 8(2) 7(2) 6(18) 1(<1) 1(3)
Others (renal/genitourinary/vascular/syndromes) 5(1) - - 5(3) 4(12)
DLTs
Dose level Total patients Patients Details about DLTs
per dose level (n) with DLT (n)
Dose level 1 4 1 Gr 3 Streptococcal infection
Dose level 2 3 0 None
Dose level 3A 6 4 Gr 3 Pulmonary infection including 3
fungal infections/ aspergillosis
Dose level 3B 6 1 Gr 3 Pulmonary infection:
fungal infection / candida albicans
Dose level 4 10 1 Gr 3 Sepsis
Dose level 5 5 2 Gr 3 Cellulitis infection (pseudomonas)
Gr 3 Sepsis
AE: adverse events; DLT: dose-limiting toxicities; Gr: grade; n: number.
27% in 11 patients with refractory 1st relapse; and 50% in
8 patients with ≥2nd relapse (Table 4). Of the 18 patients
pre-treated with FLA-DNX (refractory 1st relapse, n=11;
second relapse n=7), 6 patients (5 CR/1 CRi) responded
(33%). Three responders (1 CR/2 CRi) were seen in the
group of refractory 1st relapse patients. In the expansion
cohort at DL4 (n=10), the overall response rate was 80%
(2 CR, 5 Cri, 1 PR) (Online Supplementary Table S4). In 9 of
the 18 patients with FAB M4 and M5 AML an objective
response was seen; this was equally divided between both
groups (FAB M4 and M5). Of the 13 patients with other
FAB classifications, 9 objective responses were seen (69%,
P M4/M5 vs. other FAB 0.284).
Following clofarabine, 22 patients underwent SCT (17
MUD, 1 matched family donor, 1 HLA identical sibling
and 2 haplo-identical, 1 unknown). Of the 21 clofarabine
responding patients, 18 subsequently underwent SCT.
Overall, 9  of the 22 patients who were transplanted died
(6 MUD, 1 matched family donor, 1 haplo-identical, 1
unknown); this included 2 patients with SCT-procedure-
related deaths and one death due to lung toxicity with
CMV reactivation. The remaining patients died due to
progressive leukemia. At time of database lock, 10 of 34
patients were alive with a median survival time of 56
months (range 32.3-78.4 months). The 1-year pEFS was
35.3±8.2% and the pOS 50.0±8.6% (Figure 2A and B); the
2-year pEFS was 26.5±7.6% and the 2-year pOS
32.4±8.0%. The 1-year pEFS was 57.1±10.8% in the 21
responding patients, and the pOS was 71.4±9.9%; the 2-
year pEFS was 42.9±10.8% and the  pOS 47.6±10.9%
(data not shown). Most events in the 21 responders were
due to relapse (Figure 2C). In the 10 patients treated at the
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Figure 2. Survival estimates after clofarabine combination chemotherapy reinduc-
tion. (A) Overall survival of all patients. (B) Event-free survival of all patients. (C)
Cumulative Incidence of relapse of the 21 responding patients. (D) Overall survival
of all patients at dose level (DL) 4. (E) Event-free survival of all patients at DL4. N:




RP2D at DL4, both 1-year pEFS and pOS were
60.0±15.5%, while  2-year pEFS was 50.0±15.8% and 2-
year pOS 60.0±15.5% (Figure 2D and E). 
Pharmacokinetic analysis
Blood samples were available from the first 19 patients,
after which collection of PK data was halted after interim
analysis. Comparison of normalized plasma concentra-
tions at day 5 pre-dose and 24 hours (h) after the last infu-
sion of clofarabine showed similar results with a median
concentration of 0.12 and 0.10 ng/mL/mg, indicating a
steady state plasma concentration. The median AUC at
day 1 was 28.0 ng/mL/mg/h (range 6.0 to 401.2) and 44.0
ng/mL/mg/h (range 19.4 to 135.9) at day 5. Clofarabine
t1/2 was identical at day 1 and day 5 (average value of 1.5
h) (Online Supplementary Figure S3A).
Clofarabine levels in CSF (n=11) ranged from 0.3 ng/mL
to 3.2ng/mL [median CSF penetration (CSF conc/plasma
conc) was 32.9% (range 8.0-66.5%)]. These data are in
contrast with the previously reported low clofarabine
median penetration of 5% (range 3-26%) into the CSF in
non-human primates.30
Bonate et al.31 have fit clofarabine single-agent PK data
derived from 3 clinical trials (i.e. the ID99-383 study
recruiting pediatric hematologic malignancies, the CLO-
212 study in pediatric ALL, and the CLO-222 study in
pediatric refractory AML) using a non-parametric LOESS
fit to the observed dose normalized concentration-time
plot. Our clofarabine PK data fitted well with the Bonate
et al. 2004 PK model (Figure 3B), confirming that the cur-
rent combination did not alter clofarabine PK.
Furthermore, our PK data in combination were not signif-
icantly different from our data with single-agent clofara-
bine in relapsed ALL patients,32 suggesting that clofarabine
has no major drug-drug interaction with either cytarabine
or daunorubicin which can affect clofarabine PK.
Discussion
In this phase IB study,  the RP2D of clofarabine in com-
bination with cytarabine and DNX was established at 40
mg/m2/day for five consecutive days in combination with
60 mg/m2 DNX at days 1, 3 and 5 and cytarabine 2
gram/m2 for five days in patients with no clinical evidence
of subclinical fungal infections at time of treatment. This
regimen resulted in a high ORR of 68% in 31 response
evaluable patients, and 80% at the RP2D (n=10). 
In general, the combination of clofarabine, liposomal
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daunorubicin and high-dose cytarabine was well-tolerated
in our cohort of patients. Most observed adverse events
were as expected (febrile neutropenia and infections, gas-
trointestinal symptoms, dermatological manifestations
and pain). Our data on infections are comparable to the
single agent study in pediatric relapsed AML (67% of
patients experienced ≥grade 3 infections).13 The highest
dose level, however, appeared not to be tolerable, again
due to infectious complications. It might be that the high-
er anthracycline dose of 80 mg/m2 DNX can be tolerated
in newly diagnosed patients, but this was not assessed in
our study. The RP2D of clofarabine (40 mg/m2) was higher
compared to the CLOUD study (30 mg/m2/d for 5 days),25
but lower than clofarabine (52 mg/m2/d for 5 days) in
combination with 1 gram/m2 of Ara-C  without anthracy-
clines.24
The ORR of 68% observed with this combination regi-
men is extremely encouraging. In addition, this response
rate is higher compared than the  single-agent study13 and
the CLOUD study,25 and is for instance also higher than in
our prior study with single-agent Mylotarg.33 Patients with
early 1st relapse (n=15) responded in 93%, whereas in the
AML 2001/01 study only 70% (treated with FLAG-DNX)
and 54% (treated with FLAG) responded, although a dif-
ferent definition for response was used (≤ 20% blasts in
BM after cycle 1).2 The number of responding patients (3
of 10) who were refractory to FLA-DNX chemotherapy
given directly before clofarabine is also interesting,
although it cannot be excluded that this was the effect of
repeated chemotherapy. This was also observed in the
AML 2001/01 study where 20% of patients responded
after the second FLAG course who were not in CR after
the first course.2 However, we have to consider that, in
our cohort, we observed a low response rate among the
refractory 1st relapse patients (CR 2 of 10, Cri 1 of 10).
Our response and survival data are in accordance with
the data reported for the COG AAML0523 study.24 Of
interest, 90% of the patients in this study (that combined
cytarabine 1 g/m2 with clofarabine 52 mg/m2) were in 1st
relapse, while the remaining 10% of patients had refracto-
ry disease. The combination of cytarabine and clofarabine
in the COG study resulted in an ORR of 48% in 48 evalu-
able patients, and 21 of 23 responders underwent SCT.
The overall survival rate at 3 years was 46% for respon-
ders.24 In our study, 10 of 34 patients were still alive at last
follow up, with a 2-year pOS 32±8%. This was even high-
er in responding patients: 2-year pOS 48±11%. 
A phase III, randomized, double-blind, placebo-con-
trolled trial was recently published in 320 adults over 55
years of age with relapsed/refractory AML, comparing
cytarabine 1 g/m2 plus clofarabine 40 mg/m2 versus cytara-
bine with placebo.27 This study showed significantly
improved response rates and enhanced EFS in patients
treated with clofarabine and cytarabine compared to
placebo and cytarabine. However, no significant impact
on survival was achieved, probably related to the higher
incidence of mortality in the clofarabine arm.27 This is in
line with the randomized study performed by Burnett et
al.18 However, the recent study from Löwenberg et al.19 did
show that intermediate risk AML patients in the clofara-
bine arm benefitted compared to cytarabine in the stan-
dard arm, including a survival benefit. Children can usual-
ly tolerate higher dosages of chemotherapy, certainly
when compared to elderly patients, and the dosages used
in the adult studies were very low compared to the regi-
men that we tested here. Better salvage regimens in
relapsed pediatric AML, as summarized in various
papers,34,35 including ours, have contributed to better sur-
vival rates of patients with pediatric AML in the last
decade, together with improved supportive care meas-
ures.3
Allogeneic SCT is considered the standard treatment in
relapsed pediatric AML in Europe after re-induction with
salvage chemotherapy. In our study, 22 patients under-
went SCT following the clofarabine combination regi-
men. No particular toxicities (e.g. veno-occlusive disease)
(data not shown) were noted during the SCT procedure, and
pre-treatment with this chemotherapy combination did
not preclude a successful SCT procedure. 
Pharmacokinetic analysis showed no difference
between data obtained with single agent clofarabine in
prior studies versus clofarabine in combination in this
study. Moreover, we demonstrated that cerebrospinal
fluid (CSF) penetration was limited in CSF samples taken
approximately 24 h after the last clofarabine infusion. To
the best of our knowledge, this study is the first to study
CSF penetration of clofarabine. 
The results of this trial indicate high efficacy of the com-
Clofarabine in pediatric AML
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Table 4. Response after cycle 1 by disease status and after prior treatment with FLA-DNX.
All patients Early 1st relapse Refractory 1st relapse ≥  2nd relapse
All patients Pre-treated All patients Pre-treated All patients Pre-treated All patients Pre-treated 
n=34 n=18 n=15 n=0 n=11 n=11 n=8 n=7
Morphological response 31 15 15 10 10 6 5
Evaluable (100%) (100%) (100%) (100%) (100%) (100%) (100%)
CR 5 (16%) 1 (7%) 4 (27%) 1 (10%) 1 (10%)
CRi 15 (48%) 5 (33%) 9 (60%) 2 (20%) 2 (20%) 4 (67%) 3 (60%)
PR 1 (3%) 1 (7%)
NEL 0 0
SD 6 (19%) 5 (33%) 1 (7%) 3 (30%) 3 (30%) 2 (33%) 2 (40%)
PD 3 (10%) 3 (20%) 3 (30%) 3 (30%)
Treatment failure 1 (3%) 1 (7%) 1 (10%) 1 (10%)
FLA: fludarabine, cytarabine (Ara-C); CR: complete remission; DNX: liposomal daunorubicin; n: number; CRi: morphological complete remission with incomplete blood count
recovery; NEL: no evidence of leukemia; PR: partial response; SD: stable disease; PD: progressive disease.
N.K.A. van Eijkelenburg et al.
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bination of clofarabine, liposomal daunorubicin and high-
dose cytarabine, while having an acceptable toxicity pro-
file, even in heavily pre-treated patients. Of interest, clo-
farabine has been taken forward in front-line treatment in
the AML-BFM 2012 study (EudraCT: 2013-000018-39) as
an induction randomization, albeit low-dose cytarabine is
used rather than high-dose. 
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